Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Immuron Ltd Develops oral antibodies from bovine colostrum for digestive and immune health.	United States of America	IMRN
IMPACT BIOMEDICAL INC. Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.	United States of America	IBO
Imunon, Inc. Developing DNA-based immunotherapies for oncology and infectious diseases.	United States of America	IMNN
IN8BIO, INC. Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.	United States of America	INAB
Incanthera plc Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.	United Kingdom	INC
INCYTE CORP Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.	United States of America	INCY
Indaptus Therapeutics, Inc. Develops immunotherapies using engineered bacteria to treat cancer and viral infections.	United States of America	INDP
Indivior PLC Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.	United Kingdom	INDV
INDIVIOR PLC A pharmaceutical firm developing medicines for addiction and serious mental illnesses.	United States of America	INDV
Infant Bacterial Therapeutics Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.	Sweden	IBT